Work

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors

Year: 2014

Type: article

Source: Oncogene

DOI: 10.1038/onc.2013.562

Authors: S I Labidi-Galy, A Clauss, V Ng, S Duraisamy, K M Elias, H-Y Piao, E Bilal, R A Davidowitz, Y Lu, G Badalian-Very, B Györffy, U-B Kang, S Ficarro, S Ganesan, G B Mills, J A Marto, R Drapkin

Institutions: Harvard University, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Rutgers Cancer Institute, The University of Texas MD Anderson Cancer Center, Hungarian Academy of Sciences

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of Neurological Disorders and Stroke

Awards: G204658482, Elafin as a biomarker in serous ovarian cancers and basal-like breast tumors, Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery, Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE, Molecular Mechanisms of Fate Choice in Neural Stem Cells (P01), G846490933

OpenAlex ID: W2015939473

FWCI: 3.762

Cites: 67

Cited by: 57

Related to: 10